Decheng Capital
Latest statistics and disclosures from Decheng Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are CGON, NUVB, UPB, AARD, Lyell Immunopharma, and represent 88.13% of Decheng Capital's stock portfolio.
- Added to shares of these 1 stock: Lyell Immunopharma.
- Reduced shares in these 10 stocks: MRUS (-$18M), UPB, KRYS, CRNX, NAMS, Helix Acquisition Corp, AURA, RVMD, BYSI, ILMN.
- Sold out of its positions in GRAL, ILMN, Helix Acquisition Corp, MRUS.
- Decheng Capital was a net seller of stock by $-32M.
- Decheng Capital has $743M in assets under management (AUM), dropping by 29.70%.
- Central Index Key (CIK): 0002010850
Tip: Access up to 7 years of quarterly data
Positions held by Decheng Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Decheng Capital
Decheng Capital holds 19 positions in its portfolio as reported in the December 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Cg Oncology (CGON) | 35.6 | $265M | 6.4M | 41.52 |
|
|
| Nuvation Bio (NUVB) | 31.3 | $233M | 26M | 8.96 |
|
|
| Upstream Bio (UPB) | 11.5 | $85M | -4% | 3.1M | 27.15 |
|
| Aardvark Therapeutics (AARD) | 6.9 | $51M | 3.9M | 13.12 |
|
|
| Lyell Immunopharma | 2.9 | $21M | +16% | 692k | 30.78 |
|
| Newamsterdam Pharma Co Nv (NAMS) | 2.8 | $21M | -9% | 592k | 35.08 |
|
| Revolution Medicines (RVMD) | 2.1 | $16M | -4% | 200k | 79.65 |
|
| Arcus Biosciences Incorporated (RCUS) | 1.7 | $13M | 542k | 23.83 |
|
|
| Aclaris Therapeutics (ACRS) | 1.6 | $12M | 4.0M | 3.01 |
|
|
| Equillium (EQ) | 0.9 | $6.9M | 4.4M | 1.55 |
|
|
| BeyondSpring SHS (BYSI) | 0.8 | $6.2M | -11% | 3.8M | 1.63 |
|
| Crinetics Pharmaceuticals In (CRNX) | 0.6 | $4.3M | -35% | 93k | 46.55 |
|
| Krystal Biotech (KRYS) | 0.6 | $4.3M | -46% | 17k | 246.54 |
|
| Aura Biosciences (AURA) | 0.3 | $2.0M | -30% | 361k | 5.45 |
|
| Zentalis Pharmaceuticals (ZNTL) | 0.2 | $1.8M | 1.3M | 1.35 |
|
|
| Pyxis Oncology (PYXS) | 0.1 | $376k | 327k | 1.15 |
|
|
| 4d Molecular Therapeutics In (FDMT) | 0.0 | $332k | -52% | 44k | 7.50 |
|
| Nuvation Bio Warrants (NUVB.WS) | 0.0 | $213k | 646k | 0.33 |
|
|
| Rezolute (RZLT) | 0.0 | $141k | 60k | 2.36 |
|
Past Filings by Decheng Capital
SEC 13F filings are viewable for Decheng Capital going back to 2023
- Decheng Capital 2025 Q4 filed Feb. 12, 2026
- Decheng Capital 2025 Q3 filed Nov. 14, 2025
- Decheng Capital 2025 Q2 filed Aug. 13, 2025
- Decheng Capital 2025 Q1 filed May 8, 2025
- Decheng Capital 2024 Q4 filed Feb. 14, 2025
- Decheng Capital 2024 Q3 filed Nov. 15, 2024
- Decheng Capital 2024 Q2 filed Aug. 14, 2024
- Decheng Capital 2024 Q1 filed May 14, 2024
- Decheng Capital 2023 Q4 filed Feb. 12, 2024